NCT02073526View on ClinicalTrials.gov

Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

CompletedOBSERVATIONAL
Enrollment

1,230

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

November 30, 2016

Conditions
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Interventions
DRUG

Infliximab, adalimumab, certolizumab pegol

Patients are treated with the above mentioned drugs decided by clinicians

Trial Locations (1)

0424

Rikshospitalet-Radiumhospitalet HF, Oslo University Hospital, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT02073526 - Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter